DURECT CORPORATION (DRRX)

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...

DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023

DRRX stock results show that Durect beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Durect (NASDAQ:DRRX) just reported results for the fourth quarter of 2023.Durec...

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a...

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River...

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer...

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate...

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...

HC Wainwright downgrades DURECT to neutral, removes price target (NASDAQ:DRRX)

HC Wainwright downgrades DURECT (DRRX) after a Phase 2b study failure of its drug larsucosterol in the treatment of severe alcohol-associated hepatitis. Read more here.

Wednesday Sector Laggards: Drugs, Television & Radio Stocks

Cantor Fitzgerald Is Souring on Lucid Motors (LCID) Stock

Lucid Motors stock is falling after Cantor Fitzgerald analysts downgraded LCID shares and cut their price target following its Q3 earnings.

Why Is Sleep Number (SNBR) Stock Down 40% Today?

Sleep Number stock is falling on Wednesday as investors in SNBR react to the company missing EPS and revenue estimates for Q3.

Why Is Durect (DRRX) Stock Down 64% Today?

Durect stock is taking a beating on Wednesday as DRRX investors react to results from a Phase 2b clinical trial of larsucosterol.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.

Durect stock drops as lead drug fails in mid-stage trial

Durect Corporation (DRRX) lost 63% on Wednesday as a mid-stage study for its lead drug larsucosterol fails in alcohol-associated hepatitis patients. Read more here.

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day mortality...

3 Promising Biotech Stocks That Will Make Early Investors Rich

Despite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies.

Northland sees DURECT's upcoming data as

Northland Capital Markets said it expects upcoming mid-stage data for DURECT’s (DRRX) drug larsucosterol to serve as a “major” near-term catalyst for the stock. Read more here.

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update....